EGFR and non-small cell lung carcinoma: The clinical activities of anlotinib in EGFR mutant NSCLC patients with oligoprogressive disease following first or second-line EGFR TKI therapy were explored in the single arm phase 2 ALTER-L001 trial showing that the addition of anlotinib to EGFR TKI therapy led to a median PFS of 9.1 months and an overall response rate (ORR) of 6.7% (Chen et al., 2025).